

Minutes of the Meeting of the ESH Scientific Council

**Milan, June 21, 2019
8:30 - 12:00 hrs**

Present

K. Tsioufis, President
E. Lurbe, Vice President
R. Kreutz, Secretary
M. Burnier, Treasurer
E. Agabiti Rosei, Immediate Past President

ESH Council members

M. Azizi
A. Januszewicz
T. Kahan
J. Polonia
P. van de Borne
B. Williams

Executive officers

G. Mancia
G. Parati
D. Clement
A. Coca
A. Manolis

Ex-officio members

C. Borghi
D. Lovic

Further Participants

M. Massaro - AIM
R. Lynch

1. PRESIDENT'S WELCOME

The meeting was opened by the ESH President K. Tsioufis who welcomed Council members to the Annual Meeting. He was pleased to see all Council members present. He thanked the local members for organizing the meeting.

2. MINUTES OF THE MILAN SCIENTIFIC COUNCIL MEETING, MARCH, 2019

The minutes of the Council Meeting held in Milan, March 2nd, 2019 were unanimously accepted by the Council.

3. TREASURER'S REPORT

a. ESH

M. Burnier presented the audited financial report at 31.12.2018. The report detailed the Society's financial situation as stable notwithstanding a negative net result for the year amounting to -241'065 Swiss francs. The total assets of the ESH amount to 1'898'922 Swiss francs and the total ESH reserve amounts to 1'059'329 Swiss francs. After a brief discussion on whether the cash reserve should be invested, it was agreed the safest approach is to keep the cash reserve in the bank. K. Tsioufis suggested transferring €200,000 to FESH. This suggestion was unanimously accepted by the Council.

**European Society of
Hypertension**
Zug

**Report of the
statutory auditors to the
General Meeting**
**on the financial statements
2018**



**Report of the statutory auditors
on the limited statutory examination to the General Meeting of
European Society of Hypertension**
Zug

As statutory auditors, we have examined the financial statements of European Society of Hypertension, which comprise the balance sheet, profit and loss statement and notes, for the year ended 31 December 2018.

These financial statements are the responsibility of the Board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of association personnel and analytical procedures as well as detailed tests of association documents as considered appropriate in the circumstances. However, the testing of the operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the association's articles of incorporation.

PricewaterhouseCoopers SA


Pierre-Alain Dévaud

Audit expert
Auditor in charge


Otto Walther

Audit expert

Lausanne, 18 June 2019

Enclosure:

- Financial statements (balance sheet, profit and loss statement and notes)



European Society of Hypertension, Zug

 Balance sheet as at 31 December
(in Swiss francs)

Assets	Notes	2018	2017
Current assets			
Cash and cash equivalents	3	1'059'329	1'261'222
Short-term investments with a quoted market price		516'759	539'211
Securities (cost price)		703'915	703'915
Valuation on securities		-187'156	-164'703
Trade receivables		201'364	149'055
due from third parties		-	-
Other current receivables		-	2'179
due from third parties		-	-
Accrued income and prepaid expenses		121'469	117'015
Total assets		1'990'922	2'068'682
Liabilities			
Short-term liabilities			
Other short-term liabilities		11'259	-
due to third parties		11'259	-
Accrued expenses and deferred income		89'309	292'73
Total short-term liabilities		109'578	292'73
Equity			
Society capital		536'045	536'045
Retained earnings		1'503'364	1'012'887
Net result for the year		-241'065	490'477
Total Equity		1'798'344	2'039'409
Total liabilities		1'990'922	2'068'682

European Society of Hypertension, Zug

 Profit and loss statement for the financial year
ended 31 December
(in Swiss francs)

	Notes	2018	2017
Net proceeds from services		1'321'795	1'582'159
Subscriptions		237	382
Various meeting income		81'764	197'338
Income Meeting Barcelona		1'114'239	-
Income Meeting Milan		-	1'266'488
Royalties received		129'556	117'951
Donations		97'024	-
Services sold		-1'496'033	-1'122'753
Allowances to the Foundation of the ESH		-360'450	-
Donations		-110'408	-
Various meeting costs		-79'586	-69'923
Expenses Meeting Barcelona		-911'356	-
Expenses Meeting Milan		-	-1'041'502
Awards granted		-	-11'328
Joint ESCESH Guidelines for the mgmt of Arterial Hypertension		-34'233	-
Other operating expenses		-107'859	-91'760
Administrative costs		-12'703	-8'062
Legal and professional fees		-18'954	-22'235
other expenses		-5'328	-8'006
Bank charges		-7'730	-3'543
Website expenses		-53'145	-49'914
Financial income		255	128'554
Dividend and interest on securities		255	248
Gain on securities		-	41'357
Gain on currency exchange		-	89'949
Financial expenses		-48'448	-
Loss on securities		-22'452	-
Loss on currency exchange		-23'996	-
Extraordinary, non-recurring or prior-period income		-	2'277
Result before taxes		-231'285	498'477
Direct taxes		-8'600	-8'000
Net result for the year		-241'065	490'477



European Society of Hypertension, Zug

 Notes to the financial statements
(in Swiss francs)

1 Accounting principles applied in the preparation of the financial statements

These financial statements have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations (Art. 957 to 963b CO, effective since 1 January 2013). Significant balance sheet items are accounted for as follows:

Foreign currency translation

Assets and liabilities in foreign currencies are translated at year-end rates, whilst transactions in foreign currencies and the profit and loss accounts are translated at monthly average exchange rates published by the Federal Tax Administration (ESTV).

	2018	2017
- Closing rate for 1 USD	0.9363	0.9745
- Closing rate for 1 EUR	1.1269	1.1702

Short-term investments with a quoted market price

Short-term investments are held as liquidity reserves. They are stated at market value as per balance sheet date. A fluctuation reserve was established in respect of the risk related to share investments.

Trade receivables

Trade receivables and other short-term receivables are carried at their nominal value. Impairment charges are calculated for these assets on an individual basis.

Recognition of revenue

Revenues comprise all proceeds from the sale of the ESH's "services". Revenues from "services" are calculated on the basis of the service actually provided to the customer up to the balance sheet date. These revenues are recognised if the amount of revenue can be reliably measured and it is sufficiently probable that the economic benefits will flow to the ESH.

Details, analyses and explanations to the financial statements

2 The society does not employ any staff.

3 Cash and cash equivalents

CHF	2018	2017
UBS AG, Zürich (CHF)	107'569	169'221
UBS AG, Zürich (USD)	103'650	4'849
UBS AG, Zürich (EUR)	848'111	1'091'152
Total cash	1'059'329	1'261'222

 4 Significant events occurring after the balance sheet date
none

b. ESH FOUNDATION

M. Burnier presented the audited financial report of the Foundation of ESH at 31.12.2018. The total assets amount to 494'171 Swiss francs. The net result for the year amounts to 208'628 Swiss francs and the total cash reserve amounts to 441'468 Swiss francs.



G. Mancia informed the Council that K. Tsioufis is a new member on the Board of the Foundation.

Foundation of the European Society of Hypertension

Zug

Report of the statutory auditors to the Board on the financial statements 2018



Foundation of the European Society of Hypertension, Zug

Balance sheet as at 31 December (in Swiss francs)

Assets	Notes	2018	2017
Current assets			
Cash and cash equivalents	3	441'468	240'546
Short-term investments with a quoted market price		39'744	40'461
Securities (cost price)		58'334	58'334
Valuation on securities		-18'590	-17'843
Trade receivables		12'959	9'248
due from third parties		1'890	9'248
due from ESH		11'269	-
Total current assets		494'171	290'286
Total assets		494'171	290'286
Liabilities			
Short-term liabilities			
Trade payables		10'397	6'000
due to third parties		10'397	6'000
Accrued expenses and deferred income		6'961	16'000
Total short-term liabilities		17'257	22'000
Equity			
Foundation capital		700'000	700'000
Retained earnings		-431'715	-350'978
Net result for the year		208'628	-75'737
Total Equity		476'913	268'285
Total liabilities		494'171	290'286



Report of the statutory auditors on the limited statutory examination to the Board of Foundation of the European Society of Hypertension Zug

As statutory auditors, we have examined the financial statements of Foundation of the European Society of Hypertension, which comprise the balance sheet, profit and loss statement and notes, for the year ended 31 December 2018.

These financial statements are the responsibility of the Board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of foundation personnel and analytical procedures as well as detailed tests of foundation documents as considered appropriate in the circumstances. However, the testing of the operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the foundation's deed and the internal regulations.

PricewaterhouseCoopers SA

Pierre-Alain Dévaud
Audit expert
Auditor in charge

Otto Walther
Audit expert

Lausanne, 18 June 2019

Enclosure:

- Financial statements (balance sheet, profit and loss statement and notes)



Foundation of the European Society of Hypertension, Zug

Profit and loss statement for the financial year ended 31 December (in Swiss francs)

	Notes	2018	2017
Net proceeds from services		398'745	14'664
Allowances from the European Society of Hypertension		360'450	-
Subscriptions of Organisations		19'644	6'490
Contributions to Summer School		11'239	-
Contributions to Educational Meeting		11'411	5'851
General meeting income		-	2'324
Services sold		-149'484	-74'355
Foundation activities: Summer School		-139'087	-62'504
Foundation activities: Educational Meeting		-10'397	-11'851
Other operating expenses		-13'558	-25'346
Administrative costs		-8'719	-21'024
Legal and professional fees		-3'731	-3'888
Bank charges		-1'108	-435
Financial income		929	10'826
Dividend and interest on securities		929	902
Gain on currency exchange		-	9'924
Financial expenses		-28'033	-15'25
Loss on securities		-748	-15'25
Loss on currency exchange		-27'285	-
Net result for the year		208'628	-75'737



Foundation of the European Society of Hypertension, Zug

 Notes to the financial statements
(in Swiss francs)

1 Accounting principles applied in the preparation of the financial statements

These financial statements have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations (Art. 957 to 963b CO, effective since 1 January 2013). Significant balance sheet items are accounted for as follows:

Foreign currency translation

Assets and liabilities in foreign currencies are translated at year-end rates, whilst transactions in foreign currencies and the profit and loss accounts are translated at monthly average exchange rates published by the Federal Tax Administration (ESTV).

	2018	2017
- Closing rate for 1 USD	0.9959	0.9745
- Closing rate for 1 EUR	1.1289	1.1702

Short-term investments with a quoted market price

Short-term investments are held as liquidity reserves. They are stated at market value as per balance sheet date. A fluctuation reserve was established in respect of the risk related to share investments.

Trade receivables

Trade receivables and other short-term receivables are carried at their nominal value. Impairment charges are calculated for these assets on an individual basis.

Recognition of revenue

Revenues comprise all proceeds from the sale of the ESH's "services". Revenues from "services" are calculated on the basis of the service actually provided to the customer up to the balance sheet date. These revenues are recognised if the amount of revenue can be reliably measured and it is sufficiently probable that the economic benefits will flow to the ESH.

Details, analyses and explanations to the financial statements

2 The foundation does not employ more than 10 full time equivalents.

3 Cash and cash equivalents

CHF	2018	2017
UBS AG, Zürich (CHF)	4407	130'899
UBS AG, Zürich (USD)	3748	7'913
UBS AG, Zürich (EUR)	428'913	101'835
Total cash	441'468	240'546

4 Significant events occurring after the balance sheet date

none

Foundation of the European Society of Hypertension, Zug

 Balance sheet as at 31 December
(in Swiss francs)

Assets	Notes	2018	2017
Current assets			
Cash and cash equivalents	3	441'468	240'546
Short-term investments with a quoted market price		39'744	40'481
Securities (cost price)		56'334	58'334
Valuation on securities		-18'590	-17'843
Trade receivables		12'950	9'248
due from third parties		1'900	9'248
due from ESH		11'269	-
Total current assets		494'171	290'286
Total assets		494'171	290'286

Liabilities	Notes	2018	2017
Short-term liabilities			
Trade payables		10'397	6'000
due to third parties		10'397	6'000
Accrued expenses and deferred income		6'861	16'000
Total short-term liabilities		17'257	22'000

Equity

Foundation capital	700'000	700'000
Retained earnings	-431'715	-359'978
Net result for the year	208'628	-75'737

Total Equity	476'913	268'285
Total liabilities	494'171	290'286

Foundation of the European Society of Hypertension, Zug

Profit and loss statement for the financial year

ended 31 December

(in Swiss francs)

	Notes	2018	2017
Net proceeds from services		398'745	14'664
Allowances from the European Society of Hypertension		360'450	-
Subscriptions of Organisations		15'844	6'490
Contributions to Summer School		11'239	-
Contributions to Educational Meeting		11'411	5'951
General meeting income		-	2'324
Services sold		-149'484	-74'355
Foundation activities: Summer School		-139'087	-52'504
Foundation activities: Educational Meeting		-10'397	-11'851
Other operating expenses		-13'558	-25'346
Administrative costs		-8'719	-21'024
Legal and professional fees		-7'731	-3'888
Bank charges		-7'108	-435
Financial income		929	10'626
Dividend and interest on securities		929	902
Gain on currency exchange		-	9'924
Financial expenses		-28'003	-15'25
Loss on securities		-748	-15'25
Loss on currency exchange		-27'255	-
Net result for the year		208'628	-75'737

Foundation of the European Society of Hypertension, Zug

Notes to the financial statements

(in Swiss francs)

1 Accounting principles applied in the preparation of the financial statements

These financial statements have been prepared in accordance with the provisions of commercial accounting as set out in the Swiss Code of Obligations (Art. 957 to 963b CO, effective since 1 January 2013). Significant balance sheet items are accounted for as follows:

Foreign currency translation

Assets and liabilities in foreign currencies are translated at year-end rates, whilst transactions in foreign currencies and the profit and loss accounts are translated at monthly average exchange rates published by the Federal Tax Administration (ESTV).

	2018	2017
- Closing rate for 1 USD	0.9858	0.9745
- Closing rate for 1 EUR	1.1289	1.1702

Short-term investments with a quoted market price

Short-term investments are held as liquidity reserves. They are stated at market value as per balance sheet date. A fluctuation reserve was established in respect of the risk related to share investments.

Trade receivables

Trade receivables and other short-term receivables are carried at their nominal value. Impairment charges are calculated for these assets on an individual basis.

Recognition of revenue

Revenues comprise all proceeds from the sale of the ESH's "services". Revenues from "services" are calculated on the basis of the service actually provided to the customer up to the balance sheet date. These revenues are recognised if the amount of revenue can be reliably measured and it is sufficiently probable that the economic benefits will flow to the ESH.

Details, analyses and explanations to the financial statements

2 The foundation does not employ more than 10 full time equivalents.

3 Cash and cash equivalents

CHF	2018	2017
UBS AG, Zürich (CHF)	4407	130'899
UBS AG, Zürich (USD)	3748	7'913
UBS AG, Zürich (EUR)	428'913	101'835
Total cash	441'468	240'546

4 Significant events occurring after the balance sheet date

none




4. ESH 2019

The annual meeting is the most important activity of the Society and K. Tsioufis thanked G. Mancina and M. Massaro for the excellent organization of the 2019 ESH meeting in Milan.

a. Report on 2019 ESH Meeting, Milan

M. Massaro summarized the status of the 2019 Annual Meeting in Milan.

A total of 1079 abstracts were received. 961 Abstracts and 118 Late-breaker Abstracts. 107 were not included in the Abstract Book due to non-payment of registration fee and 22 were withdrawn by the authors. The countries with the highest number of abstracts submitted were Russia, Italy, Greece, Romania, Spain, China, Ukraine and South Korea. The e-Supplement 1 – ESH Abstract Book was published in the June edition of the Journal of Hypertension and is available on the Journal of Hypertension website and the ESH website. The cost of the online publication was approximately €9.000,00.



281 Faculty members were invited. The 2019 ESH meeting hosted 2 Satellite Symposia (Servier, Merck KGaA), 8 Minisymposia (Alfasigma, Medtronic, Menarini (2), Omron EU, ReCOR, Servier (2)) and 2 Educational Sessions (Medtronic, Sanofi).

The 2019 ESH meeting hosted 27 Exhibitors in a total surface of approx. 490 SQM. The total number of registered participants in 2019 is 2300.

A new initiative proposed to sponsors' in 2019 was the Web-TV. Merck purchased the sponsorship and their Satellite Symposium was transmitted on Sunday June 23rd using the Web-TV to 3 different audiences in 3 languages (English, Chinese, Russian). A royalty for the sponsorship has been recognized to ESH.

To celebrate the 30 years of ESH, the book published by K. Tsioufis will be distributed to all participants attending the meeting. A memory wall has been created in the exhibition area with photos of past ESH presidents and where attendees are invited to post photos of previous meetings. Gadgets will be distributed at the ESH booth. Following the opening ceremony, a 30-year anniversary cake will be cut by the ESH President and Chair of the meeting.

M. Massaro highlighted that sponsors' have been very supportive this year. The final preliminary result is €95.000,00. The final numbers will be provided at the Council meeting in November. K. Tsioufis thank M. Massaro for the great work done.

ESH BOOTH

PROVISIONAL

Please note that the minimum values guaranteed to the ESH and to the LOC are already calculated in this prospect. (€ 100.000,00 each)

Sponsorship incomes – confirmed (+ € 56.339 - ESH 2018)	€ 873.714
Registrations - updated to 20-06-2019 (- € 186.041 - ESH 2018)	€ 921.291
Expenditures - preliminary	€ 1.700.00
PRELIMINARY RESULT	€ 95.000

b. Awards

In April 2019 the Awards Call for Nominations was posted on the ESH website and an email was sent to all ESH members. The deadline date for nominations was May 5th, 2019.

The ESH Awards committee:

K. Tsioufis
 E. Agabiti Rosei
 E. Lurbe
 G. Mancia
 R. Kreutz

selected from the nominations received the below awardees.

4.b ESH 2019 AWARDS

- Björn Folkow Award – Prof. Josep Redon
- Alberto Zanchetti Life Achievement Award – Prof. Giuseppe Mancia
- ESH Honorary Membership – Prof. Renata Cifková
- Pieter A. van Zwieten Award – Prof. Maria S. Fernandez-Alfonso
- Servier Research Grant in Hypertension – Dr Marijana Tadic
- Talal Zein Award – Prof. Claudio Borghi
- Paul Milliez Award – Prof. Bernard Chamontin
- AIM Research Award in the name of Prof. Alberto Zanchetti
Dr Alexandros Kasiakogias – Dr Tamara Knežević



c. Individual meetings with Presidents of National Societies

For the second year, a series of short individual meetings, 24 in total, with the Presidents of the National Societies were organized. The meetings were held each morning over the 3 days of the meeting and the discussions revolved around how to attract, involve and motivate young physicians in the field of hypertension. The suggestion to follow up with Summer School attendees and involve them in the ESH Working Groups was well received by all the society presidents. Mutual collaboration and future co-operation with the Societies was also discussed.

D. Lovic finished his term as ESH representative of the National Societies. The Presidents of the National Societies were invited to vote online from 29/05/19 to 06/06/19. The Presidents' of 16 National Societies selected as their new representative by a large majority of votes M. Dorobantu (Romania) as the new Ex-officio Representative of the Presidents of ESH Affiliated Societies.

A Plenary Session for National Societies was proposed to be included in the annual meeting program for 2020.

d. Briefing for ESH tasks during 2019 Annual Meeting

A Task Sheet was distributed to all Council Members as a “pro memoria” of their involvement in events during the annual meeting.

5. ESH COUNCIL 2019-2018 REPORT BY PRESIDENT

K. Tsioufis provided a retrospective of the past two years as President of ESH.

He thanked the Council Members for their support during his presidency. He said that having served first as a member and then as secretary of the Society had been a great help to him as President.

The highlights of the report were: the updating of the ESH by-laws, the introduction of online voting, establishing rotation of duties of the Council members, efforts to give global visibility to the Society, the Educational Activities carried out by ESH in Europe, Latin America and China, the publication of the ESC/ESH Hypertension Guidelines in 2018, ESH publications (ESH Manual of Hypertension, Consensus documents, Position Papers, Clinical Newsletters), collaboration with National Societies and Research Projects (ESH BP control study, Emergency-Urgency Project, FMD Project), and the publication of the 30 Years of ESH.

6. ESH COUNCIL AND ESH PRESIDENT

a. Nomination for ESH Council Members

Regular elected and voting members

Regular Members' current status

P"Van"de"Borne
K"Tsioufis
E"Agabiti"Rosei"
M"Azizi
B"Jelakovic
T"Kahan
B"Williams
R"Kreutz
E"Lurbe
M"Bochud
A"Januszewicz
J"Polonia

As per the ESH by-laws, the Scientific Council is formed by 11 elected members. M. Bochud stepped down in 2018 due to heavy workload in her new professional position in Lausanne; and J. Polonia was nominated as the new ESH Treasurer. His nomination will be officially confirmed during the General Assembly.

Four Council members have finished their first 4-year term. The Council was asked to confirm the second 4-year term of these members. No-one opposed, official confirmation will be made during the General Assembly.

Regular Members current status

P"Van"de"Borne	
K"Tsoufis	
E"Agabiti"Rosei"	
M"Azizi	
B"Jelakovic	
T"Kahan	
B"Williams	
R"Kreutz	To be confirmed for second
E"Lurbe	4 year term
M"Bochud	
A"Januszewicz	
J"Polonia	

End of term members: 2 members will leave the Council.

Regular Members current status

P"Van"de"Borne	
K"Tsoufis	End of term – leaving members
E"Agabiti"Rosei"	
M"Azizi	
B"Jelakovic	
T"Kahan	
B"Williams	
R"Kreutz	To be confirmed for second
E"Lurbe	4 year term
M"Bochud	
A"Januszewicz	
J"Polonia	

The below nominations and applications for ESH Council Members were received. K. Tsoufis thanked D. Lovic and G. Parati who withdrew their applications. He also extended his thanks to the E. Agabiti Rosei as Immediate Past President and P. Van de Borne for their dedication to the Society.

Nominations and applications for ESH Council Members

- J. Brguljan
- C. Delles
- M. Dorobantu
- G. Grassi*
- M. Kanbay
- P. Legrady
- D. Lovic
- G. Parati
- A. Persu
- E. Reznik*
- J. Vaclavik
- T. Weber



Two positions on the Council were eligible for election. An open discussion followed on each of the candidates and the Council members stated their preferences. All Council members agreed on the need to involve more young members and women on the Council. The Council unanimously agreed on the below two candidates, their nomination will be officially confirmed during the General Assembly:

- G. Grassi (Italy)
- T. Weber (Austria)

Ex-officio members

Presidents of the National Societies were invited to send their online vote for the new ESH representative of the National Societies. 16 Presidents casted their vote and elected with a large majority M. Dorobantu (Romania) as stated above.

Executive members

The below members were nominated Executive members of the Scientific Council:

Nominations and applications for ESH Council Members

- J. Brguljan – coordinator of Summer Schools
- C. Delles – representative for ESH/ISH Glasgow meeting 2020
- M. Dorobantu – has been elected by National Presidents as representative
- M. Kanbay – relationship with Turkish Society will be discussed
- A. Persu – coordinator of the Working Groups



And the following proposals were made:

- P. Van de Borne (Belgium) – ESH Representative for contacts with the EU Officers. K. Tsioufis thanked D. Clement for his many years of work in this position.
- E. Agabiti Rosei – Representative for Far East Relations
- D. Lovic – ESH Endorsement Programme
- G. Parati – eHealth Technologies. After the Glasgow meeting in 2020, G. Parati will take over as the Ex-officio ISH representative.

b. Nomination of next ESH President

As Immediate Past President, E. Agabiti Rosei had the honor of announcing the new President of the Society. He informed the Council that only one nomination for the candidature had been received from Council members. He announced that R. Kreutz (Germany) shall be the new President of the ESH. The Council unanimously approved. The nomination will be officially confirmed during the General Assembly.

R. Kreutz said it was a pleasure and an honor to be elected and thanked the Council members. The outgoing President, K. Tsioufis wished him a successful presidency.

R. Kreutz nominated A. Januszewicz (Poland) as the new ESH Secretary, unanimously confirmed by the Council. His nomination will be officially confirmed during the General Assembly.

The new Immediate Past President is K. Tsioufis.

E. Lurbe accepted the invitation to continue as Vice-President.

Duties of the Council members will be confirmed during the Council meeting in November.

7. ESH AND JOURNAL OF HYPERTENSION

a. G. Mancia informed the Council that the Milan group has been re-appointed until 2021. He also reported some members of the Advisory Board have been replaced and the organization of the Journal should be decentralized to give more freedom to the Associate Editors. The impact factor of the Journal has slightly increased and the Journal of Hypertension is the second top journal in the field of hypertension. Between 1300 and 1400 papers are received yearly. The number of papers from China has increased considerably. An important issue is Open Access to articles and should be discussed with the Publisher.

b. New ISH Secretariat

R. Kreutz informed the Council that the ISH has changed their Secretariat. As from 1 June 2019 all ISH Secretariat activities have been transferred to the society In Conference. It is important to understand the agreement between ESH and the previous Secretariat with regards to the services provided and put in place a new agreement with In Conference or with the previous Secretariat (Conference Collective) to ensure limited disruption to members and collection of membership fees.

8. ESH FUTURE MEETINGS

a. ESH/ISH Meeting Glasgow

M. Massaro provided the Council with an update on the progress of the organization of the meeting.

Abstract submission will open September 15, it was suggested to start advertising now abstract submission dates.

The 2020 ESH/ISH meeting is very close to the EUROPCR meeting. M. Massaro will start contacting pharma now to try to secure sponsorship for Satellite Symposia.

Medtronic has confirmed Symposium plus Web-TV.

b. 2021 ESH Meeting, Milan

Nothing to report.

c. 2022 ESH Meeting, Athens

Nothing to report.

d. 2023 ESH Meeting, Milan

Nothing to report.

e. 2024 Bid Meeting Candidature

The members of the Bid Committee will be nominated in Berlin during the Council Meeting. Bid proposals, presentations and final decision will be made in Glasgow.

9. HYPERTENSION SUMMER SCHOOLS

a. 2019 Athens (Greece), 14-20 September

K. Tsioufis reported 67 participants from 36 countries (32 European countries and 4 non-European countries).

b. 2020 Sremski Karlovci (Serbia), 12-18 September

D. Lovic reported preparations are being made for the 2020 Summer School.

c. 2021 TBD

G. Parati - Northern Italy

M. Azizi - France

To be discussed and decided in Berlin during the Council meeting.

d. 2022 - Open for proposals

10. ESH WORKING GROUPS

a. Announcement of new WG.

An ongoing discussion is underway to form a task force to create a WG on drug treatment including safety issues and adherence. Proposals for title of the WG:

- Antihypertensive Therapy and Adherence
- BP Management and Adherence

b. Collaboration with the STRIDE-BP Organization

ESH officially supports the initiative.

c. Any other WG Topics

E. Lurbe proposed D. Stabouli as the new Vice President of the WG on Hypertension in Children and Adolescents.

11. ESH RESEARCH PROJECTS

a. BP Control Study

B. Jelakovic reported the study is being carried out in 21 Excellence Centres in 6 European countries. Approximately 1000 patients have been enrolled. Between 4-5000 enrollments are expected by the end of the year. Data will be presented at the 2020 meeting in Glasgow.

12. ESH NEWSLETTERS FOR 2019-2020

a. Clinical Newsletters

Four new Clinical Newsletters were published in 2020.

b. Meeting Endorsements:

- 4th Clinical Update Sleep™ “Auxosleep Workshop”, May 18th, 2019 in Milan (Italy).
- ICHCA – The 2nd International Congress of Hypertension in Children and Adolescents May 24-26, 2019 – Warsaw (Poland).
- V ème Congres International June 27 – 28, 2019 – Oran (Algeria).
- PCM 2019 – Patient Centered Meeting on Diabetes, Hypertension, Hyperlipidemia October 31-November 2, 2019 – Vienna (Austria).

13. DATES FOR FUTURE COUNCIL MEETINGS

a. Berlin (Germany), November 2, 2019

b. Glasgow (United Kingdom, January 25, 2020)

14. ANY OTHER ISSUES

No additional issues were brought forward for discussion.

15. CLOSURE OF THE MEETING

K. Tsioufis thanked all the ESH Scientific Council members for attending and for the productive meeting. He again thanked all the Council members for their collaboration over the last two years and wished the new President all the best.



Konstantinos Tsioufis
ESH President



Reinhold Kreutz
ESH Secretary